Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

The Impact of Anti-HLA Antibodies on the Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome

Tiantian Xie, Runqing Lu, Weijie Cao, Bian Zhilei, Wei Li, Zhongxing Jiang, Yongping Song, Dengju Li, Rong Guo

Blood (2024) 144 (Supplement 1): 7419.

https://doi.org/10.1182/blood-2024-206974

Published: 2024

Journal Articles

Inhibition of NFS1 Induces Ferroptosis and Activates Immune Response in Acute Myeloid Leukemia Cells through STAT1/ISG Pathway

Ying Liu, Bingxin Qian, Xiaoya Cai, Guiqing Huang, Dengju Li

Blood (2024) 144 (Supplement 1): 6107.

https://doi.org/10.1182/blood-2024-207185

Published: 2024

Journal Articles

Imbalanced Expression of TACI Isoforms Regulated By TNFRSF13B Variants Promotes the Progression of Epstein-Barr Virus-Associated Lymphoproliferative Diseases

Xinyue Deng, Qiang Gao, Kefeng Shen, Wei Mu, Tong Ge, Jiachen Wang, Jianfeng Zhou, Yicheng Zhang, Dengju Li, Min Xiao

Blood (2024) 144 (Supplement 1): 125.

https://doi.org/10.1182/blood-2024-193440

Published: 2024

Journal Articles

Type I Interferon Impairs the Function of CAR-T Cells By Disrupting Immune Synapse Assembly

Meijuan Huang, Lei Zhao, Yuhang Cheng, Liang Huang, Jianfeng Zhou, Dengju Li, Jue Wang, Yang Cao

Blood (2024) 144 (Supplement 1): 3407.

https://doi.org/10.1182/blood-2024-197968

Published: 2024

Journal Articles

The Expression of BTG1 in De Novo AML Patients Regulated By Demethylation of Decitabine and Its Evaluation in the Deep Remission of Patients

Shiyuan Zhang, Mengyuan Li, Xiaojian Zhu, Hao Zhou, Bin Xu, Xiwen Tong, Su Shuai, Yi Zhu, Yi Xiao, Liang Huang, Dengju Li, Wei Huang, Jia Wei, Mei Huang, Donghua Zhang

Blood (2024) 144 (Supplement 1): 1401.

https://doi.org/10.1182/blood-2024-205864

Published: 2024

Journal Articles

A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia

Blood (2024) 144 (Supplement 1): 2879.

https://doi.org/10.1182/blood-2024-198959

Published: 2024

Journal Articles

Improving CAR-T Cell Function through a Targeted Cytokine Delivery System Utilizing CAR Target-Modified Extracellular Vesicles

Yuanyuan Zhang, Meijuan Huang, Tianjiao Liu, Yuhang Cheng, Dengju Li, Yang Cao, Wei Mu, Liting Chen, Li Zhu, Tongjuan Li, Liang Huang, Jia Wei, Lei Zhao, Jue Wang

Blood (2024) 144 (Supplement 1): 3419.

https://doi.org/10.1182/blood-2024-206731

Published: 2024

Journal Articles

Efficacy of Decitabine in Combination with IA Versus IA in Patients with Newly Diagnosed AML, a Multicenter, Prospective, Randomized Controlled Trial

Xiwen Tong, Bin Xu, Shiyuan Zhang, Xiaojian Zhu, Mengyuan Li, Su Shuai, Yi Zhu, Zhenqian Huang, Yaya Wang, Yi Xiao, Liang Huang, Dengju Li, Wei Huang, Jia Wei, Mei Huang, Zhiping Huang, Yuanyan Tang, Hongbo Ren, Donghua Zhang

Blood (2024) 144 (Supplement 1): 4276.

https://doi.org/10.1182/blood-2024-205769

Published: 2024

Journal Articles

Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia：Updated Results from a Phase I Study

Blood (2023) 142 (Supplement 1): 4281.

https://doi.org/10.1182/blood-2023-188961

Published: 2023

Journal Articles

Dose Adjustments of Linperlisib in Relapsed or Refractory Follicular Lymphoma: A Post-Hoc Analysis of a Pivotal Phase II Study

Blood (2023) 142 (Supplement 1): 6140.

https://doi.org/10.1182/blood-2023-180373

Published: 2023

Journal Articles

Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results

Blood (2023) 142 (Supplement 1): 3039.

https://doi.org/10.1182/blood-2023-181500

Published: 2023

Journal Articles

Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow up

Yuqin Song, Keshu Zhou, Dengju Li, Jianda Hu, Dehui Zou, Sujun Gao, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Ru Feng, Jie Jin, Fangfang Lyu, Cheng Fang, Sheng Xu, Jun Zhu

Blood (2023) 142 (Supplement 1): 1682.

https://doi.org/10.1182/blood-2023-181352

Published: 2023

Journal Articles

PI3Kδ Inhibitor Linperlisib As a ≥ 3-Line Treatment for Relapsed or Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase II, Single-Arm, Open-Label Trial

Blood (2023) 142 (Supplement 1): 1677.

https://doi.org/10.1182/blood-2023-178710

Published: 2023

Journal Articles

Targeted Delivery of IL-12 Via CD19-Modified Extracellular Vesicles Enhances CAR-T Cell Efficacy Against Lymphoma

Meijuan Huang, Lei Zhao, Dengju Li, Liang Huang, Jue Wang, Yuanyuan Zhang

Blood (2023) 142 (Supplement 1): 6798.

https://doi.org/10.1182/blood-2023-180860

Published: 2023

Journal Articles

Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kδ Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 6145.

https://doi.org/10.1182/blood-2023-177820

Published: 2023

Journal Articles

Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis

Blood (2022) 140 (Supplement 1): 6501–6503.

https://doi.org/10.1182/blood-2022-162135

Published: 2022

Journal Articles

Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patients

Blood (2021) 138 (Supplement 1): 46.

https://doi.org/10.1182/blood-2021-149350

Published: 2021

Journal Articles

Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) Lymphomas

Junning Cao, Zhiming Li, MD PhD, Jianfeng Zhou, MD PhD, Dongmei Ji, MD PhD, Weina Shen, PhD, Peng Sun, MD, Yu Wang, MD, Dengju Li, MD, Zhenya Hong, MDPhD, Gaoxiang Wang, MDPhD, Xianlin Duan, MD, Chen Yu, MD, Yu Cai, PhD, Weiguo Su, PhD

Blood (2020) 136 (Supplement 1): 38.

https://doi.org/10.1182/blood-2020-136013

Published: 2020

Journal Articles

Comparison of Subcutaneous Injection Versus Intravenous Infusion of Cytarabine for Induction Therapy in Young Adult Acute Myeloid Leukemia: Results of a Prospective, Multicenter, Noninferiority, Randomized Trial

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-143426

Published: 2020

Journal Articles

Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy

Wenyue Cao, Jia Wei, Na Wang, Hao Xu, Min Xiao, Lifang Huang, Yang Cao, Chunrui Li, Yi Xiao, Chaojiang Gu, Shangkun Zhang, Dengju Li, Yichen Zhang, Tongcun Zhang, Jianfeng Zhou, Liang Huang

Blood (2020) 136 (4): 516–519.

https://doi.org/10.1182/blood.2020004907

Published: 2020

Includes: Supplemental data

NARROW

The Impact of Anti-HLA Antibodies on the Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome

Inhibition of NFS1 Induces Ferroptosis and Activates Immune Response in Acute Myeloid Leukemia Cells through STAT1/ISG Pathway

Imbalanced Expression of TACI Isoforms Regulated By TNFRSF13B Variants Promotes the Progression of Epstein-Barr Virus-Associated Lymphoproliferative Diseases

Type I Interferon Impairs the Function of CAR-T Cells By Disrupting Immune Synapse Assembly

The Expression of BTG1 in De Novo AML Patients Regulated By Demethylation of Decitabine and Its Evaluation in the Deep Remission of Patients

A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia

Improving CAR-T Cell Function through a Targeted Cytokine Delivery System Utilizing CAR Target-Modified Extracellular Vesicles

Efficacy of Decitabine in Combination with IA Versus IA in Patients with Newly Diagnosed AML, a Multicenter, Prospective, Randomized Controlled Trial

Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia：Updated Results from a Phase I Study

Dose Adjustments of Linperlisib in Relapsed or Refractory Follicular Lymphoma: A Post-Hoc Analysis of a Pivotal Phase II Study

Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results

Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow up

PI3Kδ Inhibitor Linperlisib As a ≥ 3-Line Treatment for Relapsed or Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase II, Single-Arm, Open-Label Trial

Targeted Delivery of IL-12 Via CD19-Modified Extracellular Vesicles Enhances CAR-T Cell Efficacy Against Lymphoma

Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kδ Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma

Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis

Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patients

Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) Lymphomas

Comparison of Subcutaneous Injection Versus Intravenous Infusion of Cytarabine for Induction Therapy in Young Adult Acute Myeloid Leukemia: Results of a Prospective, Multicenter, Noninferiority, Randomized Trial

Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only